Literature DB >> 26497515

Fcγ receptor pathways during active and passive immunization.

Stylianos Bournazos1, Jeffrey V Ravetch1.   

Abstract

IgG antibodies are actively produced in response to antigenic challenge or passively administered as an effective form of immunotherapy to confer immunity against foreign antigens. Their protective activity is mediated through their bifunctional nature: a variable Fab domain mediates antigen-binding specificity, whereas the constant Fc domain engages Fcγ receptors (FcγRs) expressed on the surface of leukocytes to mediate effector functions. While traditionally considered the invariant domain of an IgG molecule, the Fc domain displays remarkable structural heterogeneity determined primarily by differences in the amino acid sequence of the various IgG subclasses and by the composition of the complex, Fc-associated biantennary N-linked glycan. These structural determinants regulate the conformational flexibility of the IgG Fc domain and affect its capacity to interact with distinct types of FcγRs (type I or type II FcγRs). FcγR engagement activates diverse downstream immunomodulatory pathways with pleiotropic functional consequences including cytotoxicity and phagocytosis of IgG-coated targets, differentiation and activation of antigen presenting cells, modulation of T-cell activation, plasma cell survival, and regulation of antibody responses. These functions highlight the importance of FcγR-mediated pathways in the modulation of adaptive immune responses and suggest a central role for IgG-FcγR interactions during active and passive immunization.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Fc receptors; antibodies; immunotherapies; inflammation; vaccination

Mesh:

Substances:

Year:  2015        PMID: 26497515      PMCID: PMC7556827          DOI: 10.1111/imr.12343

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  149 in total

1.  Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs.

Authors:  Benjamin M Fiebiger; Jad Maamary; Andrew Pincetic; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

2.  Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid.

Authors:  Hans U Scherer; Diane van der Woude; Andreea Ioan-Facsinay; Hanane el Bannoudi; Leendert A Trouw; Jun Wang; Thomas Häupl; Gerd-R Burmester; André M Deelder; Tom W J Huizinga; Manfred Wuhrer; René E M Toes
Journal:  Arthritis Rheum       Date:  2010-06

3.  Fcgamma receptor-mediated mitogen-activated protein kinase activation in monocytes is independent of Ras.

Authors:  G Sánchez-Mejorada; C Rosales
Journal:  J Biol Chem       Date:  1998-10-16       Impact factor: 5.157

4.  Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.

Authors:  R A Clynes; T L Towers; L G Presta; J V Ravetch
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

5.  SHIP recruitment attenuates Fc gamma RIIB-induced B cell apoptosis.

Authors:  R N Pearse; T Kawabe; S Bolland; R Guinamard; T Kurosaki; J V Ravetch
Journal:  Immunity       Date:  1999-06       Impact factor: 31.745

6.  Fc gamma RIIIA-mediated signaling involves src-family lck in human natural killer cells.

Authors:  C Pignata; K V Prasad; M J Robertson; H Levine; C E Rudd; J Ritz
Journal:  J Immunol       Date:  1993-12-15       Impact factor: 5.422

Review 7.  The coordination of signaling during Fc receptor-mediated phagocytosis.

Authors:  Joel A Swanson; Adam D Hoppe
Journal:  J Leukoc Biol       Date:  2004-10-05       Impact factor: 4.962

8.  Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity.

Authors:  Stylianos Bournazos; Florian Klein; John Pietzsch; Michael S Seaman; Michel C Nussenzweig; Jeffrey V Ravetch
Journal:  Cell       Date:  2014-09-11       Impact factor: 41.582

9.  FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

Authors:  Wu Zhang; Michael Gordon; Anne M Schultheis; Dong Yun Yang; Fumio Nagashima; Mizutomo Azuma; Heung-Moon Chang; Eva Borucka; Georg Lurje; Andy E Sherrod; Syma Iqbal; Susan Groshen; Heinz-Josef Lenz
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

10.  The high affinity Fc gamma receptor (CD64) induces phagocytosis in the absence of its cytoplasmic domain: the gamma subunit of Fc gamma RIIIA imparts phagocytic function to Fc gamma RI.

Authors:  Z K Indik; S Hunter; M M Huang; X Q Pan; P Chien; C Kelly; A I Levinson; R P Kimberly; A D Schreiber
Journal:  Exp Hematol       Date:  1994-07       Impact factor: 3.084

View more
  55 in total

Review 1.  The Role and Function of Fcγ Receptors on Myeloid Cells.

Authors:  Stylianos Bournazos; Taia T Wang; Jeffrey V Ravetch
Journal:  Microbiol Spectr       Date:  2016-12

Review 2.  Beyond Viral Neutralization.

Authors:  George K Lewis; Marzena Pazgier; David T Evans; Guido Ferrari; Stylianos Bournazos; Matthew S Parsons; Nicole F Bernard; Andrés Finzi
Journal:  AIDS Res Hum Retroviruses       Date:  2017-02-16       Impact factor: 2.205

3.  An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques.

Authors:  Zhanna Shubin; Weizhong Li; Bhawna Poonia; Guido Ferrari; Celia LaBranche; David Montefiori; Xiaoping Zhu; C David Pauza
Journal:  Clin Vaccine Immunol       Date:  2017-06-05

Review 4.  Diversification of IgG effector functions.

Authors:  Stylianos Bournazos; Jeffrey V Ravetch
Journal:  Int Immunol       Date:  2017-07-01       Impact factor: 4.823

Review 5.  Developments in therapy with monoclonal antibodies and related proteins.

Authors:  H Michael Shepard; Gail Lewis Phillips; Christopher D Thanos; Marc Feldmann
Journal:  Clin Med (Lond)       Date:  2017-06       Impact factor: 2.659

Review 6.  Signaling by Antibodies: Recent Progress.

Authors:  Stylianos Bournazos; Taia T Wang; Rony Dahan; Jad Maamary; Jeffrey V Ravetch
Journal:  Annu Rev Immunol       Date:  2017-04-26       Impact factor: 28.527

7.  Lysibodies are IgG Fc fusions with lysin binding domains targeting Staphylococcus aureus wall carbohydrates for effective phagocytosis.

Authors:  Assaf Raz; Anna Serrano; Christine Lawson; Maneesha Thaker; Tricia Alston; Stylianos Bournazos; Jeffrey V Ravetch; Vincent A Fischetti
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-20       Impact factor: 11.205

Review 8.  Immunological responses to influenza vaccination: lessons for improving vaccine efficacy.

Authors:  Taia T Wang; Stylianos Bournazos; Jeffrey V Ravetch
Journal:  Curr Opin Immunol       Date:  2018-05-10       Impact factor: 7.486

9.  Neutralizing Antibodies Inhibit Chikungunya Virus Budding at the Plasma Membrane.

Authors:  Jing Jin; Jesús G Galaz-Montoya; Michael B Sherman; Stella Y Sun; Cynthia S Goldsmith; Eileen T O'Toole; Larry Ackerman; Lars-Anders Carlson; Scott C Weaver; Wah Chiu; Graham Simmons
Journal:  Cell Host Microbe       Date:  2018-08-23       Impact factor: 21.023

10.  HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.

Authors:  Till Schoofs; Florian Klein; Malte Braunschweig; Edward F Kreider; Anna Feldmann; Lilian Nogueira; Thiago Oliveira; Julio C C Lorenzi; Erica H Parrish; Gerald H Learn; Anthony P West; Pamela J Bjorkman; Sarah J Schlesinger; Michael S Seaman; Julie Czartoski; M Juliana McElrath; Nico Pfeifer; Beatrice H Hahn; Marina Caskey; Michel C Nussenzweig
Journal:  Science       Date:  2016-05-05       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.